News | August 24, 2009

Kinetic Variable Useful for Identifying Malignant MRI-Detected Breast Lesions

Kinetic Variable Useful for Identifying Malignant MRI-Detected Breast Lesions

kinetic curves of breast

August 24, 2009 - Breast MRI allows physicians to evaluate suspicious lesions using a variety of variables and computer-aided kinetic information can help significantly in distinguishing benign from malignant suspicious breast lesions on MRI, according to a study published in the September issue of the American Journal of Roentgenology (AJR). In the study, performed at the University of Washington Medical Center, researchers analyzed and compared the computer-aided evaluation variables of 125 suspicious breast lesions. Three different kinetic curves (washout, plateau and persistent), were compared along with lesion morphology (size and shape). Researchers wanted to clarify which, of the many variables that reflect kinetics, were most predictive of malignancy. The investigators found overlap in kinetic patterns across benign and malignant lesions, but did determine that the "most suspicious" curve type, washout, was useful in separating benign from malignant lesions. According to Constance Lehman, MD, lead author of the study, of the lesions with the most suspicious curve type (any washout), 45.7 percent were malignant compared with 20.0 percent with plateau and 13.3 percent with entirely persistent enhancement. "We continue to study the specific features on MRI most predictive of breast cancer. We know that the morphology of the lesion is extremely important, but our study also supports the use of kinetic features in lesion assessment. The "most suspicious" curve, washout, does seem to help distinguish benign from malignant lesions," said Dr. Lehman. For more information: www.arrs.org

Related Content

MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Videos | Breast Density | April 26, 2018
ITN Editorial Director Melinda Taschetta-Millane speaks to DenseBreast-info Executive Director JoAnn Pushkin
ACR/SBI Breast Cancer Screening Guidelines Reclassify African-American Women as High-Risk
News | Breast Imaging | April 06, 2018
New American College of Radiology (ACR) and Society of Breast Imaging (SBI) breast cancer screening guidelines are the...
ACR Recommends More Aggressive Breast Cancer Screening for Higher-Than-Average-Risk Women
News | Breast Imaging | March 29, 2018
The American College of Radiology (ACR) released new breast cancer screening guidelines recommending all women,...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital